HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.7%

Neg 0% Neu 90.7% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $102 price target.